There was only one RCT which examined initial combination therapy with an SGLT2 inhibitor and an anti-hyperglycaemic agent other than metformin, which limits assessment of the efficacy and safety of a SGLT2 inhibitor in combination with a non-biguanide type 2 diabetes drug class. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.